phase I clinical study
Fusion Pharmaceuticals, Merck to Study Targeted Radiation, Keytruda Combo in Certain Solid Cancers
The companies will conduct a Phase I/II clinical trial to evaluate Fusion's FPI-1434 and Merck's checkpoint inhibitor in solid tumors expressing IGF-1R.
Vivace Therapeutics Begins Phase I Trial of TEAD Inhibitor
The trial will include patients with mesothelioma and solid tumors that have progressed on standard treatments and harbor an NF2 mutation.
FDA Accepts IND for Clarity Pharmaceuticals' Prostate Cancer Radiopharmaceutical
Clarity will begin a Phase I/II trial of its diagnostic and therapeutic product pairing to treat PSMA-positive, metastatic prostate cancer.
Repare Therapeutics Doses First Patient in Phase I Trial of PKMYT1 Inhibitor
The trial will enroll patients with CCNE1-amplified and FBXW7-altered advanced solid tumors to explore the activity of RP-6306 as a monotherapy.
Purple Biotech, BMS Dose First Patient in Clinical Trial of CM24-Opdivo Combo
The companies plan to conduct a biomarker analysis as part of the Phase Ib/II clinical trial evaluating the anti-CEACAM1 agent plus immunotherapy for patients with advanced solid tumors.